# Exeantide in Type 2 Diabetes on Insulin

> **NCT01154933** · PHASE2 · COMPLETED · sponsor: **University at Buffalo** · enrollment: 24 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** exenatide 5 mcg
- **DRUG:** exenatide 10 mcg
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01154933
- **Lead sponsor:** University at Buffalo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01154933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01154933, "Exeantide in Type 2 Diabetes on Insulin". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01154933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*